Opinion: Bringing order to the ‘wild frontier’ of microbiome medicine

I never thought I’d someday write the sentence, “I really enjoyed that FDA meeting.” But here I am doing just that.

The topic of the meeting — regulatory implications of an emerging class of medicines to promote health by modulating the teeming microbial ecosystems that live inside each of us — may not sound like much fun, but for those of us in the field it was both enjoyable and enlightening.

, co-hosted by the National Institutes of Health, drew a packed house, filling a large conference room and two overflow rooms with clinicians, patient advocates, and industry representatives.